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ABSTRACT
Studies of the susceptibility of Plasmodium falciparum to the artemisinin family of antimalarial drugs provide a complex
picture of partial resistance (tolerance) associated with increased parasite survival in vitro and in vivo. We present an
overview of the genetic loci that, in mutant form, can independently elicit parasite tolerance. These encode Kelch propeller
domain protein PfK13, ubiquitin hydrolase UBP-1, actin filament-organising protein Coronin, also carrying a propeller
domain, and the trafficking adaptor subunit AP-2μ. Detailed studies of these proteins and the functional basis of
artemisinin tolerance in blood-stage parasites are enabling a new synthesis of our understanding to date. To guide further
experimental work, we present two major conclusions. First, we propose a dual-component model of artemisinin tolerance
in P. falciparum comprising suppression of artemisinin activation in early ring stage by reducing endocytic haemoglobin
capture from host cytosol, coupled with enhancement of cellular healing mechanisms in surviving cells. Second, these two
independent requirements limit the likelihood of development of complete artemisinin resistance by P. falciparum,
favouring deployment of existing drugs in new schedules designed to exploit these biological limits, thus extending the
useful life of current combination therapies.
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OVERVIEW OF ARTEMISININ SUSCEPTIBILITY
IN MALARIA PARASITES
Artemisinin-based combination therapy (ACT), co-formulating a
short-acting artemisinin with a long-acting partner drug, is cur-
rently recommended for uncomplicated falciparum malaria. The
artemisinin family of drugs is derived from naturally occurring
compounds produced by the wormwood Artemisia annua (You-
You et al. 1982). The widespread deployment of ACT together
with other control strategies has reduced malaria morbid-
ity and mortality, particularly in Africa (WHO 2017), but ACT
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efficacy against Plasmodium falciparum infections is threatened
by reduced parasite susceptibility to both artemisinin and its
partner drugs in the Greater Mekong subregion (GMS) (Noedl
et al. 2008; Dondorp et al. 2009; Kyaw et al. 2013; Ashley et al. 2014;
Saunders, Vanachayangkul and Lon 2014; Imwong et al. 2017a,b).
Declining ACT efficacy against P. falciparum in this region raises
concern that multidrug resistance may emerge in, or spread to,
other malaria-endemic countries (Woodrow and White 2017),
and there is some evidence of decreasing ACT effectiveness in
Africa (Beshir et al. 2013; Henriques et al. 2014; Muwanguzi et al.
2016; Yeka et al. 2016; Sutherland et al. 2017; Kone et al. 2020).
Efforts to understand the mechanism of reduced artemisinin
susceptibility in P. falciparum have focused around the in vivo
phenotype of markedly extended parasite clearance times fol-
lowing a 3-day course of artesunate monotherapy, or ACT, as
first described in the GMS by Noedl et al. (2008) and Dondorp
et al. (2009). Quantitative estimates of parasite clearance dynam-
ics were framed as either parasite reduction ratio (fraction of
initial parasitaemia remaining after 48 h of treatment) or par-
asite clearance half-life (estimated from a log-linear curve of
microscopically quantified parasitaemia) following artemisinin
monotherapy (Ashley et al. 2014). Surprisingly, slow-clearing par-
asites in vivo may be adequately cleared by 7 days of artemisinin
monotherapy, 3 days of monotherapy followed by 3 days of ACT
or a standard 3-day course of ACT (Bethell et al. 2011; Kyaw et al.
2013; Ashley et al. 2014; Nyunt et al. 2017; Rovira-Vallbona et al.
2020), so this phenotype is not functionally equivalent to the
resistance phenotype observed for many other drugs, including
chloroquine, and is best described as significantly reduced par-
asite susceptibility or increased parasite tolerance.
A recurring puzzle that arose from initial research into slow-
clearing P. falciparum in Cambodia was the poor correlation with
standard in vitro measures of artemisinin susceptibility (Noedl
et al. 2008; Dondorp et al. 2009). Witkowski et al. (2013) were suc-
cessful in establishing a reliable, if technically challenging, in
vitro correlate of in vivo clearance half-life, the ring-stage sur-
vival assay (RSA) (Fig. 1A). This method measures the fractional
survival of tightly synchronised cultured early ring-stage par-
asites [2–4 h post-invasion (p.i.)] to a 4–6 h pulse of 700 nM
dihydroartemisinin (DHA), estimated at 72 h p.i. by microscopic
counting (Witkowski et al. 2013) or flow cytometry (Fu et al. 2010;
Yang et al. 2016; Henrici, van Schalkwyk and Sutherland 2019a).
Just as post-artemisinin slow clearance in vivo does not impart
full resistance to typical treatment regimens, the reported esti-
mates of fractional in vitro survival of K13 mutant parasites in the
RSA vary dramatically between 2% and 45%, with laboratory pro-
tocols varying in the duration of drug exposure (Straimer et al.
2015; Henrici, van Schalkwyk and Sutherland 2019a, 2020). Ade-
quate standardisation to allow robust inter-laboratory compar-
isons is needed and requires widely available standard parasite
lines that can be shared among teams (see the section ’Detailed
studies of K13 mutants in vitro’). Later trophozoite-stage para-
sites are fully susceptible to a 4-h pulse of drug exposure (Klonis,
Creek and Tilley 2013; Witkowski et al. 2013; Dogovski et al. 2015;
Hott et al. 2015; Sutherland 2017), explaining why EC50 estimates
for DHA from standard assays with continuous 48–72 h drug
exposure do not correlate with slow clearance in vivo (Fig. 1B).
Given this observed temporally restricted partial resistance phe-
notype both in vivo and in vitro, we will refer to the reduced
susceptibility phenotype as ‘artemisinin tolerance’ throughout
this review. In our discussion, increased artemisinin tolerance is
manifested as either slow clearance in the artesunate- or ACT-
treated patient or higher fractional survival of parasites in the
RSA in vitro.
The establishment by Witkowski et al. (2013) of an in vitro cor-
relate for the slow parasite clearance phenotype directly enabled
identification of the genetic basis of artemisinin tolerance in
the GMS by Ariey et al. (2014). These authors confirmed genetic
mutations encoding amino acid substitutions in the carboxy
terminus of the WD40 propeller-containing protein K13 were
associated with artemisinin tolerance in parasites isolated from
patients. This protein, encoded by the pfk13 locus on P. falci-
parum chromosome 13, is characterised by six tandem Kelch
motif repeats that form a six-bladed β-propeller, a tertiary struc-
ture associated with protein recruitment for ubiquitin-mediated
turnover (Xie, Ralph and Tilley 2020). A well-studied mammalian
homologue of K13 is the human Kelch protein KEAP1, which
regulates turnover of the transcription factor Nrf2 (Lo et al.
2006). Subsequent adaptation of Cas9 and zinc finger nucle-
ase (ZFN) genome-editing technologies to P. falciparum enabled
the demonstration of a subset of these mutations in the K13
propeller domain as sufficient to elicit artemisinin tolerance
in vitro in the RSA (Ghorbal et al. 2014; Straimer et al. 2015).
More recent work suggests that these mutations elicit a partial
loss of function that effectively reduces the abundance of func-
tional K13 protein in early ring-stage parasites, slowing endo-
cytosis (see the section ’Recent functional studies of reduced
ring-stage artemisinin susceptibility’). These key advances ush-
ered in the opportunity to rigorously evaluate the associations
of novel genotypes recently discovered outside the GMS, defined
by distinct mutations in pfk13 or other genes, with artemisinin-
tolerance phenotypes in vitro (Kamau et al. 2015; Taylor et al. 2015;
Menard et al. 2016; Muwanguzi et al. 2016).
Although pfk13 mutations became a useful genetic marker
for artemisinin tolerance in clinical infections, these results
did not lead to any immediate unravelling of the underlying
resistance mechanism. This is in part due to the complexity of
artemisinin drug action. Parasite killing has been consistently
linked to parasite haemoglobin metabolism, with reduction of
the artemisinin endoperoxide bridge by iron in haem (Klonis
et al. 2013), producing oxy-radical species (Heller and Roepe
2019). These radicals are thought to cause oxidative damage
in the parasite cell through formation of artemisinin adducts
with haem and other cellular macromolecules. Proteomic stud-
ies using artemisinin probes labelled by click chemistry reveal a
large number of alkylated cellular polypeptides (Wang et al. 2015;
Ismail et al. 2016), supporting the view that biomolecular adducts
are formed stochastically by activated artemisinin endoper-
oxides (Jourdan et al. 2019). Two studies have also suggested
that artemisinins cause rapid depolarisation of the mitochon-
drial membranes, potentially as a result of interaction between
endoperoxide and iron–sulfur clusters (Wang et al. 2010; Peatey
et al. 2015). It follows that haemoglobin uptake and breakdown
is central to artemisinin activation and subsequent cytotoxi-
city, a proposal supported by the observation that disruption
or inhibition of haemoglobin-metabolising falcipain proteases
induces artemisinin tolerance in vitro (Klonis et al. 2011; Xie et al.
2016). However, the chemical activation of artemisinins has not
been clearly visualised in live cells, and the persistence of these
oxy-radical species and the limits of their diffusion through the
cytosol, mitochondrial, nuclear or lysosome compartments are
poorly defined.
Artemisinin activation and the mechanism of artemisinin
tolerance are expected to largely involve the food vacuole (FV)
of the parasite, already implicated as a site of antimalarial resis-
tance adaptation by P. falciparum. In particular, mutations in the
gene encoding the chloroquine resistance transporter in the FV
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Figure 1. RSA for artemisinin susceptibility testing is based upon variation in drug killing across the in vitro cell cycle. (A) Schematic of timing of drug exposure and
wash-off when carrying out the RSA of Witkowski et al. (2013). A 4-h pulse is shown, but this can vary in literature reports. (B) Data from Dogovski et al. (2015) redrawn
to directly compare the DHA dose response across the first 30 h of the cell cycle in vitro of four parasite isolates from Pailin, Cambodia, that differ in pfk13 genotype
as indicated. This illustrates that the tolerance phenotype is only seen in the first few hours of intra-erythrocytic growth. Schizonts from all four lines were highly
susceptible (LD50 ∼20 nM). WT—wild-type propeller domain sequence in pfk13.
by changing drug efflux across the vacuole (Fidock et al. 2000;
Eastman et al. 2011; Ross et al. 2018; Dhingra et al. 2019). In some
studies, additional copies of the gene encoding another FV pro-
tease involved in haemoglobin breakdown, plasmepsin II, have
been linked to reduced susceptibility to piperaquine (Silva et al.
1996; Amato et al. 2017). However, no clear cross-resistance has
been demonstrated in P. falciparum to date between chloroquine
or piperaquine and artemisinin, suggesting the mechanism of
artemisinin tolerance is less about the rate of haemoglobin
metabolism and haem accumulation and rather more about a
requirement for haemoglobin catabolism for drug activation.
Further, artemisinin tolerance is greatly increased in vitro by a
short pulse of low temperature or heat shock, likely to briefly
perturb many cellular processes, including haemoglobin uptake
and protein turnover in ring stages, whereas chloroquine sus-
ceptibility is unaffected (Henrici, van Schalkwyk and Suther-
land 2019a), supporting the idea that resistance mechanisms for
these two drugs are independent in P. falciparum.
Despite its importance to intra-erythrocytic parasite growth
and the action of multiple drugs, including artemisinin, the
mechanism of host cell cytosol uptake and transport to the FV
is poorly understood. Electron microscopy (EM) studies suggest
that haemoglobin enters the asexual parasite through various
endocytic processes and is first taken up into small vesicles that
are absorbed into the FV (Elliot et al. 2008; Abu-Bakar et al. 2010;
Milani, Schneider and Taraschi 2015). Structures involved in the
uptake of host cell components into parasite cytosolic compart-
ments include some labelled by phosphoinositide 3-phosphate
(PI3P) (Jonscher et al. 2019). PI3P is a phospholipid component
of endosomal membranes in other eukaryotes and has been
implicated in K13-mediated artemisinin tolerance. K13 binds
PI3P kinase (PI3K), the kinase that produces PI3P, and artificial
induction of PI3P levels increases ring-stage artemisinin toler-
ance (Mbengue et al. 2015; Bhattacharjee et al. 2018). Recently,
GFP-tagged K13 was localised to PI3P-labelled membrane com-
partments in close proximity to the parasite’s FV (Birnbaum
et al. 2017), and to peripheral structures bearing a strong resem-
blance to the parasite cytostome, a plasma membrane invagi-
nation involved in endocytosis, by 3D structured illumination
microscopy (SIM) visualisation (Yang et al. 2019).
In eukaryotes, the process of substrate-specific endocyto-
sis involves cargo selection and aggregation by the heterote-
trameric adaptor protein 2 (AP-2) complex into clathrin-coated
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Yap and Winkler 2015; Kaksonen and Roux 2018). AP-2 is one of
up to five distinct adaptor complexes that mediate endocytosis
and intracellular transport (Park and Guo 2014; Yap and Winck-
ler 2015). While AP-2 function has only recently been studied
in apicomplexans (Henrici et al. 2020), the clathrin heavy chain
and AP-1 have been localised to post-Golgi secretory structures
in P. falciparum and the related Toxoplasma gondii (Ngô et al. 2003;
Pieperhoff et al. 2013; Kaderi Kibria et al. 2015; Venogupal et al.
2017), which seem largely distinct from the structures labelled by
PI3P and K13 in P. falciparum. As in other eukaryotes, AP-2 partici-
pates in endocytosis in P. falciparum, which surprisingly seems to
be a clathrin-independent process (Birnbaum et al. 2020; Henrici
et al. 2020). AP-3 and AP-4 have not yet been studied or impli-
cated in drug responses in apicomplexans, though are likely to
participate in post-Golgi transport as in other eukaryotes. Only
one AP-5 subunit homologue is present in Plasmodium genomes
studied to date, and this occurs as a pseudogene, and so AP-5 is
unlikely to be functional.
Interestingly, genetic studies of AP-2 in Plasmodium sup-
ported a role for this complex in artemisinin susceptibility
before K13 mutations were discovered. Whole-genome associ-
ation studies in the rodent malaria species P. chabaudi first iden-
tified a mutation in the pcap2μ locus associated with experimen-
tally selected artemisinin resistance (Hunt et al. 2007; Henriques
et al. 2013). Our recent data indicate that P. falciparum expressing
the orthologue of this originally discovered P. chabaudi mutation
is tolerant to pulses of artemisinin in vitro (Henrici, van Schalk-
wyk and Sutherland 2019b), and conditional knock-sideways
of AP-2μ similarly increases artemisinin tolerance (Birnbaum
et al. 2020). Other studies have investigated the role of a distinct
pfap2μ mutation at codon 160, identified in clinical infections in
East Africa (Henriques et al. 2015).
These data provided the first link between endocytosis and
artemisinin tolerance, and in the sections that follow we will
consider in detail the proposed importance of haemoglobin
uptake to artemisinin action in Plasmodium, the impact of inter-
ference in endocytosis on cell development and drug suscep-
tibility, and the growing evidence that modulation of protein
uptake through the cytostome–endosome network is required
for parasites to survive a short exposure to DHA in vitro. We will
then attempt to synthesise current observations into a coher-
ent broader picture of the ways in which malaria parasites may
evade artemisinin-mediated killing, including consideration of
the need for surviving cells to repair any cellular damage result-
ing from artemisinin exposure. The implications of this under-
standing for future treatment strategies to prolong the useful
efficacious life of current ACT chemotherapies will also be con-
sidered.
VARIANTS OF DIVERSE PARASITE MOLECULES
CAN ELICIT RING-STAGE SURVIVAL IN VITRO
Detailed studies of K13 mutants in vitro
Initial studies of K13 polymorphisms in P. falciparum from the
GMS with extended clearance half-lives after artemisinin treat-
ment identified five mutations of interest (Ariey et al. 2014; Ash-
ley et al. 2014; Menard et al. 2016). These were in approximate
order of frequency:
 C580Y (Cambodia, Vietnam, Laos, Thailand, Myanmar)
 F446I (Myanmar, China)
 R359T (Cambodia, Vietnam, Laos)
 Y493H (Cambodia, Vietnam)
 I543T (Cambodia, Vietnam)
Evidence of in vitro impact of these mutations on RSA sur-
vival was first provided by Ghorbal et al. (2014). As a proof-of-
principle exemplar of the effectiveness of CRISPR-Cas9 genome
editing in P. falciparum, these authors engineered the pfk13 locus
of wild-type laboratory line 3D7 to encode the C580Y K13 vari-
ant, derived two independent clonal lineages and demonstrated
RSA survival estimates of 11.14% and 15.81%, respectively.
Straimer et al. (2015) then presented a major analysis of
four of the K13 variants from the GMS—C580Y, R539T, Y493H
and I543T—as well as the M476I variant originally described in
an experimentally derived artemisinin-tolerant line of Tanza-
nian origin by Ariey et al. (2014), which also occurs at low fre-
quency in Myanmar (Nyunt et al. 2015). In a classical applica-
tion of reverse genetics, deploying ZNF genome editing, Straimer
and colleagues demonstrated three important features of K13-
mediated artemisinin tolerance in vitro. First, by reverting the
endogenous K13-encoding gene back to wild type in four dif-
ferent artemisinin-tolerant lines, the main GMS variants were
shown to be sufficient to induce artemisinin tolerance in vitro
by the RSA (Straimer et al. Fig. 2A–D). Second, when introduced
into the same genetic background (chloroquine-resistant labora-
tory line Dd2), each of the five K13 variants elicited significantly
differing levels of survival in the RSA (Fig. 2J; ibid.). Third, when
introduced into five different parasite lines, the C580Y variant
elicits five different fractional survival estimates in the RSA
(Fig. 2K; ibid.), clearly demonstrating that genetic background
has a profound effect on the intensity of the tolerance pheno-
type in vitro. Additionally, an important contribution of this work
was the establishment and in vitro phenotypic characterisation
of three isogenic parasite lines of Cambodian origin, namely
the slow-clearing in vitro tolerant patient isolate Cam 3.II, which
harbours the R539T variant of K13, and Cam 3.IIREV (genome-
edited to R539R) and Cam 3.IIC580Y (genome-edited from Cam
3.IIREV). This well-characterised isogenic trio, made widely avail-
able, should serve as international standard for inter-laboratory
calibration and comparison of RSA outputs (Henrici, van Schalk-
wyk and Sutherland 2019b).
PI3P and PI3K in K13-mediated artemisinin tolerance
Mbengue et al. (2015) provided some of the first mechanistic
data underlying the phenotype of artemisinin tolerance asso-
ciated with K13 mutant genotypes. Specifically, these authors
reported that the small phospholipid PI3P and the associated
PI3K were direct targets of artemisinin. It was also observed that
expression levels of PI3K and PI3P differed in parasites express-
ing variant K13. Unlike higher order eukaryotes, the P. falciparum
genome apparently encodes only one PI3K enzyme (PfPI3K), and
in lineages expressing K13C580Y or K13R359T, the authors found
significantly higher levels of PI3K, potentially linking this fac-
tor to RSA survival. In mammalian cells, the closest K13 ortho-
logue is a ubiquitylation scaffolding factor, and the authors pro-
pose that K13 regulates PI3K levels and thus the abundance of
PI3P. However, it remains unclear how this high-level expression
might functionally contribute to the artemisinin tolerance phe-
notype, or whether it is a cellular adaptation to reduced endo-
cytic activity.
In many other eukaryotes, PI3P is a component of the early
endolysosomal system—the initial destination of endocytic traf-
ficking (Gillooly et al. 2000; Gillooly, Simonsen and Stenmark
2001). Mbengue et al. (2015) reported PI3P at the endoplasmic
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Figure 2. Two-component model for parasite survival of artemisinin treatment in vivo. Conceptual model in which two components of P. falciparum cellular biology
(endocytosis—top panel; cellular healing capacity—middle panel) contribute to survival across 48 h of intra-erythrocytic schizogony following exposure to artemisinin
treatment in vivo within an approximate ‘artemisinin exposure window’ during which suppression of Hb endocytosis can be advantageous (bottom panel). This sim-
plistic representation sees both components as binary (wild-type/reduced; basal/enhanced), but this is unlikely to hold true. Only parasites encountering artemisinin
during this ‘window’ (the first few hours of intra-erythrocytic development) may survive; later stages remain susceptible and are unlikely to survive whatever their
phenotype (not shown). Horizontal axis: hours post-invasion. Red vertical axis: relative efficiency of Hb endocytosis up to mature trophozoite stage. The alternate state
of ‘reduced Hb endocytosis’ can be generated by the presence of Kelch 13 mutations (Ariey et al. 2014; Straimer et al. 2015) that reduce the endocytic uptake (from host
cytosol) of haemoglobin entering through cytostomes or other endocytic structures (Yang et al. 2019). The arrow shows direction of benefit, which is only exerted in ring
stages. The same alternate state can be reached by expression of variants of PfCoronin (Demas et al. 2018), AP-2m, UBP-1 (Henrici et al. 2020), disruption of falcipain-2a
(Klonis et al. 2011; Xie et al. 2016) and hypo- or hyper-thermal pulses at early ring stage (Henrici et al. 2019a). Blue vertical axis: capacity for cellular healing through
adaptive modification of the proteasome, the unfolded protein response (UPR), chaperone-mediated protein re-folding, autophagy and DNA repair; the arrow shows
direction of benefit. These phenotypes have not been adequately characterised to allow a precise prediction of impact, and any particular parasite may have enhanced
capacity in only some, but not all, of these functions. It is assumed these functions are most active prior to schizogony and segregation of merozoites. Cellular healing
capacity is encoded independently of ring-stage tolerance, is thought to be multigenic and may also require epigenetic adaptations. Therefore, it is likely to be rarely
achieved, and may come at a cost to overall reproductive fitness in the absence of intense drug pressure. Green vertical axis: relative survival capability in a treated
host of parasites with each of the four combined states possible in a simplistic binary model for each of the two components—haemoglobin endocytosis and capacity
for cellular healing, respectively. In contrast to in vitro assays, damaged parasites surviving the artemisinin exposure window may be unlikely to survive host clearance
mechanisms without an enhanced cellular healing phenotype. Only the effects of an artemisinin encounter at early ring stage are shown.
with DHA relocates PI3P to the parasitophorous vacuole, a result
recapitulated by subsequent work (Bhattacharjee et al. 2018).
This localisation, and thus the mechanistic interpretation of
PI3P in artemisinin tolerance, is seemingly at odds with several
other studies (McIntosh et al. 2007; Tawk et al. 2010; Boddey et al.
2016; Ebrahimzadeh, Mukherjee and Richard 2018; Jonscher et al.
2019; Birnbaum et al. 2020), likely in part because of differences
in reporter protein used to localise PI3P in the cell. Mbengue et al.
detected PI3P via overexpression of the FYVE domain of EEA1,
a Rab5-dependent PI3P-binding protein found in other eukary-
otes, that mostly labels the early endosome where Rab5 is abun-
dant. In Plasmodium, the localisations of Rab5 family members
are not well articulated, and thus the labelling of PI3P with EEA1
is of uncertain meaning. Other studies in eukaryotes deploy
the mammalian protein p40phox, a specific PI3P-binding factor,
to avoid dependence on the EEA1 FYVE domain for PI3P local-
isation. In Plasmodium, P40phox sensing of PI3P reproducibly
demarcates the FV and apicoplast membranes and labels mem-
branes of vesicles containing host cell (haemoglobin-containing)
cytosol (Ebrahimzadeh, Mukherjee and Richard 2018), rather
than the ER as suggested by Mbengue and Bhattacharjee. In par-
ticular, Birnbaum et al. (2020) demonstrate using P40phox sens-
ing that K13 is very closely apposed to the PI3P-labelled FV and
vesicular membranes and so association with these structures
cannot be ruled out. A recent ultrastructural study reported
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cytosol-containing vesicles likely bud (Yang et al. 2019). However,
this group did not examine the localisation of K13 with respect
to PI3P reporters. Interestingly, while the role of PI3P in the story
of K13-mediated artemisinin tolerance remains unclear, several
proteomic datasets comparing isogenic wild-type and mutant
K13 lineages have been published over the last several years,
and none have identified changes in PfPI3K abundance or a
direct interaction between K13 and PfPI3K (Siddiqui et al. 2017;
Birnbaum et al. 2020; Gnädig et al. 2020). Using docking stud-
ies and molecular dynamics simulations, Mbengue et al. (2015)
suggested that ART directly inhibits PfPI3K via non-covalent H-
bonding with D1889 and Y1915 side chains, but no further data
have emerged supporting this view, and Hassett et al. (2017)
report clear evidence that functional inhibition of purified PI3K
requires covalent binding of activated endoperoxide and occurs
randomly across many molecular sites. Experimental results
discussed above (see the section ’Overview of artemisinin sus-
ceptibility in malaria parasites’) show that activated DHA pri-
marily acts through formation of covalent biomolecular adducts
by indiscriminate oxidation of macromolecules in close proxim-
ity. As a major component of the FV and endosomal/vesicular
membranes, increased PI3P abundance in K13 mutant para-
sites may be related to a lag in formation of these bi-layered
structures, which are clearly required for asexual survival. Fur-
ther functional studies are required to verify a direct role in
artemisinin tolerance of this lipid and its kinase partner.
Endocytic adapter protein subunit AP-2μ
The mechanisms by which the P. falciparum parasite internalises
and transforms haemoglobin into haemozoin are central to the
efficacy of many antimalarial drugs, and haem-derived iron is
known to catalyse the oxidative opening and activation of the
artemisinin endoperoxide moiety. Although direct inactivation
of falcipain 2a in the laboratory increases artemisinin tolerance
(Klonis et al. 2011; Xie et al. 2016), mutations in haemoglobinases
or FV transporters have not been identified as causative for
artemisinin tolerance in human infections or laboratory-evolved
lineages (Ariey et al. 2014). Hunt et al. (2007) derived artemisinin-
tolerant lineages in the rodent malaria parasite P. chabaudi, and
subsequent whole-genome sequencing revealed a mutation in
the medium subunit of the canonical eukaryotic endocytic traf-
ficking complex AP-2, invoking the possibility that haemoglobin
uptake rather than digestion might manipulate artemisinin tol-
erance (Henriques et al. 2013).
Subsequent studies in human P. falciparum infections found
evidence of directional selection on pfap2μ genetic variants dur-
ing artemisinin treatment (Henriques et al. 2014), and recent
reverse genetics experiments confirmed that AP-2μ does medi-
ate artemisinin tolerance. Specifically, Henrici, van Schalk-
wyk and Sutherland (2019b) demonstrated that when installed
into P. falciparum, the I592T mutation, orthologous to that first
described in artemisinin-resistant P. chabaudi (pcap2μ I568T),
increases RSA survival. Birnbaum et al. (2020) further demon-
strated in P. falciparum that AP-2μ inactivation via conditional
knock-sideways also causes ring-stage tolerance to artemisinin,
suggesting that the P. chabaudi mutation causes an impairment
of AP-2μ function. This is consistent with lower concentra-
tions of haemoglobin-derived peptides found in artemisinin-
tolerant parasites compared with artemisinin-sensitive para-
sites (Siddiqui et al. 2017), supporting a role for endocytosis in
artemisinin tolerance and AP-2 therein. Further evidence that
the AP-2 adaptin complex mediates ring-stage artemisinin sus-
ceptibility in P. falciparum is provided by the laboratory evolu-
tion of a parasite lineage with a measurable tolerance pheno-
type found to harbour a non-synonymous change in the AP-2α
subunit, though a reverse genetics validation of this mutation is
outstanding (Rocamora et al. 2018).
UBP-1
UBP-1 was first implicated in drug tolerance in P. chabaudi (Hunt
et al. 2007). Growth under sequential and sustained chloro-
quine, artemisinin and artesunate pressure in vivo resulted in
the appearance of non-synonymous point mutations within the
coding sequence of the putative UBP-1 locus in two clones, as
well as mutations in the locus encoding AP-2μ. Experimen-
tal introduction of the orthologous pcubp1 mutations into P.
falciparum (encoding V3275F, V3306F; Henrici et al. 2019) fol-
lowed by DHA treatment confirmed an in vitro ring-stage phe-
notype in both species for the V3275F mutant, but not the
V3360F mutant, experimentally validating the involvement of
UBP-1 in artemisinin tolerance in P. falciparum. Transgenic P.
berghei parasites expressing mutations orthologous to V3275F
and V3306F recrudesced earlier than wild-type parasites after
artesunate challenge (Simwela et al. 2020), confirming UBP-1
mediates ART tolerance in vivo, although the in vivo susceptibil-
ity assays deployed by Simwela et al. are not directly comparable
to outputs of the RSA for P. falciparum in vitro. The orthologue of
PfUBP-1(V3275F) was found to recrudesce faster than the ortho-
logue of PfUBP-1(V3306F). Interestingly, the latter mutation also
increased chloroquine tolerance in P. berghei, but this is not the
case in P. falciparum (Henrici, van Schalkwyk and Sutherland
2019b).
Amino acid substitutions within this gene have also been
identified in naturally occurring infections. In cultured P. falci-
parum isolates from Kenyan children, pfubp1 mutations outside
of the ubiquitin C-terminal hydrolase (UCH) domain were asso-
ciated with higher DHA EC50 estimates by genome-wide asso-
ciation analysis, and these isolates displayed decreased genetic
variation in a region of chromosome 1 centred on pfubp1 (Bor-
rmann et al. 2013), consistent with directional selection in the
field. In a separate study of Kenyan children, these same muta-
tions were statistically associated with ACT treatment failure,
though they have not been studied in vitro (Henriques et al. 2014).
Moreover, genomic surveillance of GMS field isolates linked an
additional point mutation within the UCH domain, encoding
R3138H, with ART resistance (Cerquiera et al. 2017), which was
recently validated in the RSA (Birnbaum et al. 2020).
Despite the genetic evidence for involvement of UBP-1 in
mediating ART tolerance, the protein remains poorly charac-
terised. The pfubp1 locus encodes a large, 415 kDa protein with
the putative UCH domain at its carboxy terminus. Although UBP-
1 has been classified as a deubiquitinating (DUB) enzyme on
the basis of this domain, its functionality in mediating ubiqui-
tin hydrolysis is hypothetical, and the potential function of the
larger upstream portion of this protein has not been explored.
PiggyBac mutagenesis studies and conditional knock-sideways
experiments have identified UBP-1 as essential and involved
in haemoglobin endocytosis (Zhang et al. 2018; Birnbaum et al.
2020); however, these data do not reveal what segment of this
protein is necessary for parasite viability nor do they provide any
clues as to its specific function. Interestingly, knock-sideways of
UBP-1 in the ring stage also induces ART tolerance (Birnbaum
et al. 2020). Thus, the mutations validated so far in vitro (V3275F
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likely to functionally disrupt the protein and its putative DUB
function. UBP-1 has not been explored in other apicomplexans
but USP7, a homologue of UBP-1, is involved in regulating endo-
cytosis and surface glycoprotein abundance in the distant try-
panosomatid protist T. brucei (Zoltner et al. 2015).
Actin-associated propeller domain protein Coronin
K13 and AP-2μ were identified as proteins of interest using
experimental artemisinin selection of well-established labora-
tory parasite lines (see above). Demas et al. (2018) examined
whether artemisinin tolerance could arise de novo in African par-
asite populations and so subjected two recently derived parasite
isolates from Senegal to long-term in vitro selection with increas-
ing concentrations of DHA. Two parasite clones were isolated,
one from each original isolate, that exhibited enhanced survival
in the ring-stage survival assay. Among 10 mutations in seven
different genes in these two clones, the gene encoding PfCoro-
nin, a WD40 propeller domain-containing actin-binding protein,
accrued mutations in both independent selections. For valida-
tion, Cas9 editing of pfcoronin to introduce the mutations of inter-
est into the susceptible parental parasites increased fractional
survival in the RSA in both cases. As seen for K13 and AP-2μ,
EC50 estimates for the transgenic parasites indicated full suscep-
tibility under continuous 72 h drug exposure in a standard assay,
in contrast to the DHA-tolerant phenotype observed in the RSA
(Demas et al. 2018). Thus, like K13 mutants, variants of PfCoro-
nin only impart artemisinin tolerance in the early ring stage of
the intra-erythrocytic cycle.
The discovery of this additional protein able to modulate
artemisinin tolerance should provide new insights into the
molecular mechanisms of resistance. The WD40 repeat domain
of PfCoronin encodes seven blades and the protein is implicated
in filamentous actin organisation in Plasmodium (Olshina et al.
2015) and other Apicomplexa. Coronin is specifically thought
to organise actin filaments required for endocytosis and recy-
cling of membranes in Toxoplasma (Salamun et al. 2014). Thus,
vesicular trafficking may be a common functional platform that
links K13, AP-2μ and Coronin to mechanisms of artemisinin tol-
erance in ring-stage parasites (Henrici and Sutherland 2018). As
the experimental selection studies that identified Coronin were
carried out in recently isolated African parasite isolates, it may
be that pfcoronin mutants could emerge as components of a K13-
independent artemisinin tolerance mechanism in natural para-
site populations.
RECENT FUNCTIONAL STUDIES OF REDUCED
RING-STAGE ARTEMISININ SUSCEPTIBILITY
Several studies independently investigating the biological mech-
anisms of artemisinin tolerance were published in 2019 and
2020, providing a complex picture of the cellular adaptations
that can elicit artemisinin tolerance in ring-stage P. falciparum
parasites in vitro.
K13 associates with the parasite cytostome
Yang et al. (2019) measured protein turnover in K13 mutant and
wild-type parasites in vitro, demonstrating that tolerance was
the result of partial loss of K13 function and providing new evi-
dence of localisation to peripheral structures in the cell that cor-
respond to the parasite cytostome. Experimental mislocalisation
of wild-type K13 to the nucleus led to 20% survival in their mod-
ification of the RSA, and reduced abundance of haemoglobin-
specific peptides (products of catabolism) in ring-stage parasites,
suggestive of reduced haemoglobin uptake. This is consistent
with the proposed involvement of cytostomes, specialised but
poorly understood parasite structures that mediate early events
in haemoglobin uptake. Specifically, each cytostome is a deep
invagination of the parasite plasma and parasitophorous vac-
uole membranes. Red cell cytosol is expected to fill this space,
and endocytic vesicles containing host cytosol are believed
to bud from the cytostome and deliver haemoglobin to the
digestive vacuole (DV) for degradation into amino acids. Using
super-resolution and EM, Yang et al. identified K13 in ring-
shaped peripheral structures with a cross-sectional diame-
ter that corresponds to the average diameter of the neck of
cytostomes, presumably forming a type of collar that could mod-
ulate haemoglobin uptake. This electron-dense cytostomal col-
lar has been previously described as anchored to organising
actin filaments implicated in the trafficking of haemoglobin to
the FV (Lazarus, Schneider and Taraschi 2008; Smythe, Joiner
and Hoppe 2008). Interestingly, as discussed above, variants of
the actin-binding protein PfCoronin also induce artemisinin tol-
erance in vitro (Demas et al. 2018).
In addition, Yang et al. (2019) examined protein turnover, cel-
lular structures and responses after short pulses of artemisinin
exposure. After DHA was applied and wild-type K13 mislocalised
to the nucleus, there was less overall protein damage, presum-
ably because of impaired endoperoxide activation, due to the
requirement for haemoglobin uptake to activate DHA (Klonis
et al. 2011). In contrast to a previous work (Zhang et al. 2017),
Yang found that wild-type and mutant K13 lineages initially
respond similarly to ring-stage ART-induced stress at the level
of protein translation, suggesting no intrinsic differences in
translation-dependent oxidative stress response. However, the
K13 mutant parasite line Cam3.IIR359T resumed protein turnover
several hours after DHA exposure, whereas wild-type Cam3.IIREV
did not despite similar basal levels of protein turnover in the
two treated groups. Yang et al. argue this is evidence against
K13-mediated latency being a key factor in artemisinin tolerance
in favour of an intrinsic difference in artemisinin activation,
although we add the obvious caveat that very few Cam3.IIREV
parasites survived the DHA pulse, making this comparison dif-
ficult to interpret. We speculate that the observation of an
extended duration of the parasite ring stage, observed in pro-
peller domain mutant parasites (Hott et al. 2015), may be a direct
result of a lower abundance of K13 reducing haemoglobin uptake
and catabolism and so starving the ring-stage parasite of key
nutrients, rather than the result of an acquired dormancy strat-
egy.
K13 defines a clathrin-independent endocytic
compartment
In unrelated work, Birnbaum et al. (2020) probe the localisa-
tion and function of K13 and provide the most in-depth mecha-
nistic interrogation of artemisinin tolerance to date, ultimately
supporting the centrality of impaired endocytosis. By imaging
an endogenously tagged transgenic K13-GFP (green fluorescent
protein) lineage, the authors show that K13 is localised to a
cytosolic compartment near the DV and apicoplast that does
not colocalise with conventional, studied Plasmodium organelles
but is also labelled by the AP-2 complex, in particular the
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authors further define the components of this compartment to
include several previously uncharacterised factors (now labelled
KIC1–KIC10), the canonical endocytic factor Eps15 and, interest-
ingly, UBP-1. Conditional ring-stage inactivation of these factors
reduces parasite uptake of fluorescent dextrans hypotonically
loaded into the RBC cytosol and induces ring-stage artemisinin
tolerance. These findings suggest that this compartment is
intimately associated with endocytosis, a process that drives
artemisinin activation in the first few hours post-invasion. Curi-
ously, this compartment was shown to be devoid of clathrin,
the canonical AP-2-interacting endocytic coat protein (see the
section ’AP-2μ associates with a clathrin-independent compart-
ment and is essential for schizogony’). Similarly, expression of
the K13C580Y mutation, widely circulating in the GMS and else-
where, also reduced endocytic uptake. Reduced endocytic dex-
tran uptake in the K13C580Y mutant was not attributable to mislo-
calisation or altered interactions but rather to an overall reduc-
tion in K13 protein abundance, in agreement with studies link-
ing artemisinin-resistant parasites with lower levels of K13 pro-
tein (Siddiqui et al. 2017; Yang et al. 2019). Exogenous overexpres-
sion of either the wild-type or mutant allele ablates ring-stage
ART tolerance in a lineage endogenously expressing K13C580Y,
further suggesting the phenotype elicited by naturally occurring
K13 mutations is related to the amount of functional protein
present.
Whereas K13 itself appears to only be essential during ring
stage, inactivation of its interactors Eps15, UBP-1 and KIC7 is
detrimental to parasite growth across all stages of development.
The disruption of UBP-1, in particular, was shown to signifi-
cantly reduce haemoglobin uptake and increased drug toler-
ance as determined by RSA (Birnbaum et al. 2020). Introduc-
tion of UBP-1R3138H, a naturally occurring mutation linked to ART
resistance in field samples, resulted in the same effects. These
results would suggest that this arginine-to-histidine change
inhibits UBP-1 function, which is consistent with the observa-
tion that it was not possible to introduce two simultaneous
mutations in the UCH domain of pbubp1 (Simwela et al. 2020).
It will be interesting to determine whether the R3138H muta-
tion, and possibly the V3275F mutation identified in P. chabaudi
by Hunt et al. (2007), results in protein instability and lower lev-
els of UBP-1 in the cell (as seen with K13 propeller mutants).
Alternatively, as they fall within or in close proximity to the
UCH domain, these point mutations may directly disable ubiq-
uitin hydrolase activity but leave overall protein abundance
unaltered.
With advanced EM imaging, Birnbaum et al. (2020) demon-
strated that the compartment labelled by K13, AP-2μ, Eps15,
UBP-1 and the other KICs is likely to be the cytostome, in agree-
ment with the data presented by Yang et al. (2019). Overall, the
authors suggest that, unlike for canonical DV-active antimalari-
als like chloroquine, the mechanism of tolerance to artemisinins
in field isolates is upstream of the DV and likely related to the
rate of haemoglobin transport to the DV, and the availability of
substrate haem-derived iron for ART activation, rather than the
rate of haemoglobin digestion and haem accumulation. Inter-
estingly, this also suggests that while potentially many muta-
tions in diverse genes could mediate ring-stage artemisinin tol-
erance, development of complete ART resistance is unlikely to
be mediated by variant components of this endocytic compart-
ment alone as haemoglobin is fundamentally required for para-
site growth.
AP-2μ associates with a clathrin-independent
compartment and is essential for schizogony
In a third unrelated work, Henrici et al. (2020) probe the locali-
sation and function of AP-2μ, one of the core factors implicated
in the genetics of artemisinin tolerance, as a window to under-
standing endocytosis in the wild-type parasite in the absence
of artemisinin pressure. AP-2μ was expected to be localised
with clathrin to peripheral membranes, but instead these factors
localised to distinct surfaces, in agreement with the results of
Birnbaum et al. (2020). Clathrin was instead found at punctae dis-
tributed throughout the cytosol, whereas AP-2μ labelled fewer
discrete structures at the plasma membrane and adjacent to
the FV. These AP-2μ-labelled structures were present through-
out the entire asexual life cycle and in the mature schizont seg-
regated into daughter merozoites to be carried into the nascent
parasites of the next generation, strikingly colocalising with K13
across each developmental stage in good correspondence with
the findings described above. EM identified AP-2μat the plasma
membrane as well as cytosolic vesicles labelled with the GTPase
cofactor Rab5B, which has been previously implicated in intra-
cellular transport at the plasma membrane and food-vacuole
membrane in P. falciparum (Ezougou et al. 2014).
Conditional DiCre-mediated genetic deletion of AP-2μ was
lethal and broadly disrupted schizont maturation, causing accu-
mulation of lipids and free haemozoin in the parasite cytosol
and tearing of parasite membranes, consistent with underlying
fragmentation of the FV and disruption of haemoglobin uptake
and lipid mobilisation or recycling. Interestingly, no deposits of
host cell cytosol were visualised in any imaging studies, as had
been seen in VPS45 knock-sideways experiments (Jonscher et al.
2019), probably because disruption of transport by VPS45 mis-
localisation occurs after vesicles have formed and been inter-
nalised, in contrast to the complete blockade of vesicle forma-
tion by AP-2μ knockout.
Co-immunoprecipitation experiments performed by Henrici
et al. (2020) identified several key factors supporting a role
for the AP-2 complex in a clathrin-independent endocyto-
sis, namely several small trafficking-associated regulators and
plasma membrane factors copurified with AP-2μ including
PfEHD, an epsin homology domain-containing factor previously
associated with endocytic machinery in Plasmodium (Thakur
et al. 2015). PfEHD contains an N-terminal dynamin-like domain,
which typically drives membrane scission during vesicular bud-
ding. Though dynamins are poorly characterised in Plasmod-
ium, Dynasore, a small-molecule inhibitor of dynamin GTPase
activity, has been demonstrated to interfere with haemoglobin
uptake in Plasmodium (Zhou et al. 2009).
Consistent with the K13 interaction studies performed by
Birnbaum et al. (2020), K13 did not copurify as an interactor
of AP-2μ despite their colocalisation. However, KIC7 (Kelch13-
interacting protein 7; Birnbaum et al. 2020) was enriched as
an AP-2μ interactor in these co-immunoprecipitations (Henrici
et al. 2020). Thus, KIC7 may be a bridging adaptor between K13
and the AP-2 complex at sites of endocytosis. Unexpectedly,
another Kelch domain-containing factor encoded on chromo-
some 10 (K10) also copurified with AP-2μ, and its interaction was
validated by reciprocal pulldown (Henrici 2018). This network
corroborates a role for endocytosis in artemisinin tolerance as
manipulations of KIC7 and AP-2μdirectly cause artemisinin tol-







sre/article/45/3/fuaa056/5936564 by London School of H
ygiene & Tropical M
edicine user on 26 M
ay 2021
Sutherland et al. 9
K13-mediated artemisinin resistance in Asian parasite isolates
(Cerqueira et al. 2017). Lastly, Henrici et al. (2020) defined the
remaining AP-2 complex subunits in P. falciparum including AP-
2α, which has been suggested to mediate artemisinin tolerance
in a laboratory-evolved lineage (Rocamora et al. 2018). Impor-
tantly, neither clathrin heavy chain nor clathrin light chain
was identified in the AP-2μ pulldowns, and AP-2 subunits were
not identified in a reciprocal clathrin heavy chain immunop-
urification, further defining artemisinin tolerance-associated
haemoglobin endocytosis as a clathrin-independent process
(see the section ’K13 defines a clathrin-independent endocytic
compartment’; Binrbaum et al. 2020).
Artemisinin tolerance is linked to functional protein
dose in K13 mutant lineages
Gnädig et al. (2020) took a different approach to elucidating
K13 cellular function and the basis of artemisinin tolerance.
Unlike the three studies described above, in which cis-tagging
of endogenous K13 and AP-2μ with haemagglutinin or GFP
reporters was deployed in immunofluorescence analyses of pro-
tein localisation and in co-immunoprecipitation approaches to
identify interacting or proximal proteins, a panel of anti-K13
monoclonal antibodies (mAb) was developed and deployed in
parallel with reporter tagging. K13 cellular distribution was
examined in isogenic Cam3.IIREV and Cam3.IIR539T lines and
a pair of lines from the artemisinin-susceptible NF54 back-
ground edited to express either wild-type K13 or the C580Y
tolerance-associated variant. Interestingly, overexpressing wild-
type K13 in either mutant background generated a pseu-
dodiploid genotype in which the artemisinin tolerance phe-
notype was greatly reduced or completely ablated. This indi-
cates that K13-mediated artemisinin tolerance is not a domi-
nant phenotype and that the R539T and C580Y mutations do not
behave as dominant Mendelian alleles. Instead, these findings
support the conclusion of Yang et al. (2019) that K13-mediated
artemisinin tolerance results from a lower dose of functional
K13 in the cell as mutations cause a partial loss of function.
Gnädig et al. (2020) estimate this to be functionally equivalent
to a 50% reduction in protein abundance in parasites carry-
ing the K13R359T allele compared with wild type, similar to the
∼30–50% reduction reported by Birnbaum et al. for K13C580Y-
expressing parasites, corresponding to an ∼30–40% reduction in
functional endocytosis (Birnbaum et al. 2020; Gnädig et al. 2020).
Consistent with these observations, Heller, Goggins and Roepe
(2018) demonstrated that ferriprotoporphyrin IX-artemisinin
adducts were significantly less abundant in artemisinin-tolerant
parasites with K13 mutations than in isogenic wild-type
parasites.
Immunofluorescence and immunoelectron microscopy (IEM)
experiments by Gnädig et al. (2020), using their anti-K13 mAb
as well as parasite lines with tagged pfk13 alleles, reported
a localisation consistent with the colocalised distributions of
AP-2μ-3xHA and K13-GFP described by Henrici et al. (2020).
K13 was reported in a single cytosolic focus during the first
few hours post-invasion, and this was observed to repli-
cate and segregate to daughter merozoites during schizogony.
Super-resolution imaging confirmed that K13-labelled struc-
tures resemble donuts or tubes, which could represent the
cytostome location described by Yang et al. (2019) and Birnbaum
et al. (2020). IEM using these monoclonal reagents frequently
identified K13 in small membrane-bound structures near the ER,
FV and plasma membrane, sometimes associating with struc-
tures likely to represent cytostomes. No differences in localisa-
tion were observed between K13 wild-type and mutant para-
sites in the absence of drug pressure. However, when exposed
to a 6-h ring-stage challenge of 700 nM DHA, wild-type K13
remained partly colocalised with several endocytosis-associated
Rab5-family GTPases, including Rab5B as reported for AP-2μ by
Henrici et al. (2020), Rab6 and Rab7, proteins expected to partici-
pate in post-Golgi transport near the DV (Siddiqui et al. 2020). The
mutant K13 molecule, on the other hand, became less closely
associated with Rab interactors, potentially as a consequence of
its reduced stability and DHA-induced cytosolic oxidation.
To identify factors interacting with K13, Gnädig et al. (2020)
performed co-immunoprecipitations using their anti-K13 MAb,
and generated a complex dataset of potential functional part-
ners, using both wild-type and K13R539T parasite lines. Interac-
tors included a significant selection of Rab family GTPase pro-
teins, recognised as regulators of targeting and fusion of traffick-
ing vesicles involved in secretion and endocytosis (Langsley et al.
2008) and partly colocalised in the imaging studies. Consistent
with the findings of Henrici et al. (2020), the list of interacting
factors did not include AP-2μ and included only a single pro-
tein (PFK9, gene ID: PF3D7 0915400) that also occurs in the list of
K13 interactors produced by Birnbaum et al. (2020). While Birn-
baum et al. (2020) fused K13 to a minimal biotin transferase to
label nearby and interacting proteins, it is striking that such an
apparently promiscuous methodology did not isolate more fac-
tors in common with the interactors identified by Gnädig et al.
(2020). An important difference between these methodologies is
that whereas the bio-ID approach operates in live cells before
lysis, immunopurification relies on the preservation of native
interactions during cell lysis and adequate solubility in the cho-
sen lysis buffer. Gnädig et al. (2020) did not identify UBP-1 or
any KIC-family proteins as interacting partners of K13 nor, in
agreement with previous studies, did they copurify PI3K. Over-
all, the data presented are consistent with an important role of
K13 in modulating haemoglobin uptake and vesicular transport
via the cytostome and Rab network. Surprisingly, these exper-
iments also suggest an unexpected involvement of the mito-
chondria, particularly in the mutant K13 response to artemisinin
pressure, as a number of mitochondrial proteins were identified
as putative interacting partners. Gnädig et al. propose that K13 is
specifically recruited to the mitochondrion. However, permeabil-
isation of the mitochondrion and loss of membrane polarisation
following artemisinin exposure have been previously described
(Wang et al. 2010; Peatey et al. 2015), and this also occurs in all
dying cells, and so may lead to inappropriate ingress of proteins
from other compartments. Given the only partial concordance
of these findings with those of Birnbaum et al. (2020), further
studies of K13 and mitochondrial function in P. falciparum are
of importance to clarify the impact of treatment and acquired
tolerance on the parasite organelle.
OXIDATION AND
PROTEOTOXICITY—THREATS TO IN VIVO
FITNESS OF ARTEMISININ-TOLERANT
PARASITES
Artemisinin-tolerant parasites have activated stress
responses and repair mechanisms
Prior to the identification of pfk13 as the major genetic determi-
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patients in the GMS, detailed genomic and transcriptomic stud-
ies had provided evidence that parasites displaying this pheno-
type were characterised by an enhanced cellular stress response.
Slow-clearing patient isolates harboured specific variants of
genes involved in DNA synthesis, mismatch repair and oxida-
tive damage response (Miotto et al. 2013; Takala-Harrison et al.
2013), and showed upregulation of stress response factors in the
ring stage and of ring-stage transcripts in otherwise trophozoite-
stage cells, despite an overall reduction in global transcription
(Mok et al. 2011). Transcripts that were significantly upregu-
lated in slow-clearing patient isolates included cyclophilin19B,
dolichyl-phosphate-mannose protein mannosyltransferase, ER-
resident calcium-binding protein, BiP/grp78, and a protein disul-
fide isomerase (Mok et al. 2015), but this group of molecules,
associated with the unfolded protein response (UPR), was highly
transcribed generally in parasites from the GMS compared with
other countries of origin in this dataset. More recently, lineages
expressing K13 mutations were found to have abnormally ele-
vated early ring-stage levels of the phosphorylated form of eIF2α,
a translationally repressive stress response factor that may play
a role in recovery from artemisinin-induced damage (Zhang et al.
2017; Yang et al. 2019). Puzzlingly, this phosphorylation event
seems to be independent from K13 activity, as conditional inac-
tivation of K13 in early ring stages has no effect on eIF2α-P lev-
els (Yang et al. 2019). Other proteomic and transcriptomic stud-
ies have revealed increased expression of stress response fac-
tors in K13 mutant ring-stage parasites, suggesting a proteo-
static mechanism may account for a delay in early cell develop-
ment (Mok et al. 2015; Siddiqui et al. 2017; Gnädig et al. 2020) and
that subsequent survival post-artemisinin exposure requires
enhanced protein turnover and oxidative damage response.
Further evidence supporting this view comes from the lab-
oratory evolution of in vitro artemisinin tolerance by Rocamora
et al. (2018). Two independent lineages of the 3D7 laboratory line
with modestly enhanced ring-stage survival and a measurable
trophozoite survival enhancement were generated by cycling of
artemisinin drug pressure over 2 years. Pfk13 mutations were not
present, but mutations in pfap2α did accrue, as did copy number-
dependent upregulation of expression of genes involved in
adaptive responses against cellular damage within the para-
site, including 6-phosphogluconate dehydrogenase, thioredoxin
1 and a signal peptidase linked to ER-associated degradation.
These authors conclude that, in at least one of their parasite
lines, resilience to artemisinin derives from an increased capac-
ity to mediate oxidative stress and protein damage, and sug-
gest that a possible mechanism for artemisinin resistance is an
enhanced ability of P. falciparum to cope with the cellular damage
presumably caused by artemisinin directly, and that this could
generate K13-independent artemisinin tolerance/resistance in
the field. The existence of such parasites is supported by the
findings of Mukherjee et al. (2017) who identified four P. falci-
parum isolates from Cambodia lacking variant K13, displaying
normal clearance dynamics in vivo but with enhanced in vitro
survival in the RSA. Conversely, no direct causative relation-
ship has yet been shown between K13 mutations and enhanced
repair of cellular damage.
Cellular healing—a requirement for parasite survival
following artemisinin treatment
The studies summarised above, considered together, suggest
that successful artemisinin tolerance in vivo leading to enhanced
parasite survival in treated patients is the biological sum of
two adaptive processes. The first is reduction of ring-stage
haemoglobin endocytosis through mutations in loci encoding
components of the endocytotic machinery of the ring-stage par-
asite such as pfk13, pfap2μ, pfcoronin and pfubp1, among others
(Xie, Ralph and Tilley 2020). The second adaptive component
is enhanced response to oxidative stress and protein damage
wrought by activated artemisinin in surviving cells (Mok et al.
2015; Rocamora et al. 2018). In this two-component model (Fig. 2),
attenuated endocytosis reduces ring-stage haemoglobin uptake
such that early ring-stage parasites encounter a reduced frac-
tion of activated, cytotoxic artemisinin. Functionally impaired
endocytosis reduces the concentration of activated artemisinin
that the parasite cell sees by transiently starving the cell of
haem iron. However, these cells are still affected by the drug
molecules that do manage to gain access to Fe2+. These acti-
vated molecules are terminally reactive warheads that cova-
lently modify proteins. Thus, resumption of cell development
and growth requires efficient repair of this damage as well
as compensation for fitness costs associated with impaired
haemoglobin uptake (Straimer et al. 2015). This is particu-
larly important in vivo where splenic clearance and innate and
acquired host immunity pose additional threats to cell survival
in the treated patient (O’Flaherty et al. 2019), in contrast to in vitro
studies, where parasite genetic mutations alone are sufficient
to mediate parasite survival in excess of 30%. Further, damaged
parasites may not be able to efficiently generate the viable game-
tocytes, needed for propagation within the circulating P. falci-
parum population. This two-component model for artemisinin
resistance (Fig. 3) also provides another plausible explanation
for why K13-mediated tolerance has not widely emerged as
major public health threat in Africa, although such parasite
phenotypes may be present in Rwanda (Uwimana et al. 2020).
The enhanced damage repair phenotypes prevalent in the GMS,
which pre-date the slow clearance phenotype, are necessary for
K13 mutants to flourish under drug pressure, but are absent in
other endemic regions. It remains unclear how enhanced cel-
lular healing and other ‘background’ phenotypes might interact
with non-K13 loci associated with ART tolerance in vitro to gener-
ate in vivo delayed clearance phenotypes in natural populations.
We have a growing understanding of the adaptive mech-
anisms by which ring-stage Hb endocytosis might be slowed
by affecting proteins in either of two inter-linked functional
groupings—the first defined by K13 and postulated to reside at
the cytostomal neck (Yang et al. 2019; Xie, Ralph and Tilley 2020),
and the second defined by AP-2 and postulated to reside at sites
of endocytosis, which may well be the cytostomal bulb (Fig. 3).
Only KIC7 has thus far been implicated as an interactor with
both complexes. In contrast, the ‘enhanced cellular healing phe-
notype’ is barely defined, so how could it be recognised and
compared between isolates? Several poorly characterised par-
asite systems may contribute to enhanced healing, suggested
as a prerequisite for clinical emergence and transmission of
artemisinin tolerance. Specific mechanisms that deserve atten-
tion in future studies are as follows.
 UPR: Are mutations or perturbations in heat-shock proteins,
ER-resident chaperones and translational cofactors required
for physiologic recovery from ART-induced damage?
 Autophagy: Do autophagy-related genes such as pfatg18
modulate ART tolerance phenotypes (Breglio et al. 2018), and
how do autophagosomes and autophagy status contribute to
protein turnover and ART-induced oxidative stress response?
 Ubiquitin-proteasome system: Do patterns and mechanisms
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Figure 3. Two-component model of in vivo artemisinin tolerance and recovery. Plasmodium falciparum survival of artemisinin exposure in vivo requires two distinct
adaptive components, as even surviving cells are likely to have sustained oxidative damage that would increase the chances of clearance by host defences (O’Flaherty
et al. 2019). Left hemisphere: Recent in vitro studies of parasite lineages displaying ring-stage artemisinin-tolerant phenotypes have revealed a common mechanism
involving dysregulation of haemoglobin endocytosis via the cytostome. Two complexes seem to be involved: K13-labelled cytostome collar complex (blue) and AP-
2-labelled cytostome cargo complex (yellow), which may be linked by KIC7 (green ellipse), a common interacting protein. Two-colour super-resolution SIM imaging
(left-most panel; Henrici 2018) of mature schizonts by the authors demonstrates the spatial relationship between these two complexes and recapitulates the ring-
shaped K13-defined structure of the cytostome collar with AP-2μ inside this ring in several optical planes. Manipulation of this common pathway leads to a decrease
in haemoglobin-derived haem in the DV, and thus a corresponding diminution of activated DHA from supra-lethal concentrations to sub-lethal concentrations (purple
and light green bars). This decrease in ring-stage haemoglobin uptake and artemisinin activation allows a fraction of cells to survive. Right hemisphere: Surviving cells
may have adaptations that mitigate oxidative damage via a variety of as-yet poorly defined pathways. Such enhanced cellular healing phenotypes synergise with the
ring-stage artemisinin tolerance phenotype to increase chances of survival in the treated immunocompetent host and enable emergence of artemisinin tolerance in
circulating parasite lineages.
sensitive and resistant lineages and contribute to the rate of
protein turnover? Are transcriptional changes in proteaso-
mal subunits required for clinical emergence of ART toler-
ance?
 Metabolism: Does recovery from ART-induced damage
require changes in mitochondrial function and energy avail-
ability?
 DNA repair mechanisms: To what extent does ART-induced
DNA and intranuclear protein or chromatin damage con-
tribute to cytopathology, and how does the cell cope with this
damage to resume normal development and faithfully prop-
agate its genome?
Some of these questions can be readily addressed using
available tools. In vitro methods are available to detect activ-
ity levels of proteins implicated in modulating the UPR,
such as eIF2α (Zhang et al. 2017), and specific inhibitors can
also be readily utilised. There also exist well-characterised
specific inhibitors of cellular actors along the ubiquitination-
proteasomal degradation pathway that could be used as
indicators of phenotypic variation in this important system for
protein turnover (Turnbull et al. 2017). Assays exist to compare
DNA repair activity between cell lines, and these have been
utilised to measure differences in effectiveness of repair post-
artemisinin exposure in P. falciparum (Xiong et al. 2020). Novel
machine learning approaches might also be used to uncover
hidden sequence-based features and mutations in these and
other factors that correlate with RSA and clinical outcomes to
better define the ‘parasite background’ that permits artemisinin
tolerance to emerge and spread.
IMPLICATIONS FOR TREATING FALCIPARUM
MALARIA IN VIVO
We are gaining new insights into the cellular functions of key
proteins implicated in modulating the susceptibility of P. falci-
parum to artemisinin in vitro and in vivo. These proteins are coa-
lescing into two groups as their identities emerge: those that
in variant forms, and/or through modified expression levels,
elicit impaired ring-stage endocytosis of haemoglobin, so reduc-
ing drug activation, and those that contribute to enhanced cel-
lular healing (Fig. 3). Ring-stage parasites with advantageous
variants in both groups, thus far described only in the GMS,
have an increased chance of surviving artemisinin exposure
in vivo, although more mature parasites are always killed, and
cellular healing of residual artemisinin-induced damage then
increases the chances that surviving cells will progress to suc-
cessful schizogony.
This conceptual model explains two observations concern-
ing P. falciparum infections in vivo that have puzzled the field.
The first is that K13 mutant parasites are completely cleared
by extended regimens of artesunate monotherapy and/or ACT
(Schallig et al. 2017; Sutherland 2017). The second is that K13
propeller domain mutations that induce artemisinin tolerance
in vitro have not spread widely in African or South American
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Mathieu et al. 2020), possibly because adaptations associated
with enhanced cellular healing are rare or absent (Mok et al.
2015; Xiong et al. 2020). It remains to be seen whether the small
focus of K13R561H mutant parasites in Rwanda, which have not
yet been shown to display a slow clearance phenotype in vivo,
represents an important exception (Uwimana et al. 2020). There
is therefore an opportunity to preserve the effectiveness of ACT
for the immediate future by exploiting this growing knowledge
of the biological limits of artemisinin tolerance. We recommend
the testing of new, imaginative schedules and regimens utilis-
ing the combination therapies we already have (van Schalkwyk
and Sutherland 2015; Schallig et al. 2017). The recent evaluation
of the so-called ‘triple ACT’ given over 3 days is a promising step
in this direction, although there was no measurable benefit over
standard single ACT regimens except in areas where the partner
drug piperaquine was failing (van der Pluijm et al. 2020). Future
studies should compare this approach with combinations given
over 6 or 7 days as a means to prevent sub-microscopic and
asymptomatic persistence of surviving parasites post-treatment
(Beshir et al. 2013; Sá et al. 2018).
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Ngô HM, Yang M, Paprotka K et al. AP-1 in Toxoplasma gondii
mediates biogenesis of the rhoptry secretory organelle from
a post-Golgi compartment. J Biol Chem 2003;278:5343–52.
Noedl H, Se Y, Schaecher K et al. Artemisinin resistance in Cam-
bodia 1 (ARC1) study consortium. Evidence of artemisinin-
resistant malaria in western Cambodia. N Engl J Med
2008;359:2619–20.
Nyunt MH, Cueto C, Smith JL et al. Clinical and molecular surveil-
lance of artemisinin resistant falciparum malaria in Myanmar
(2009–2013). Malar J 2017;16:33.
Nyunt MH, Hlaing T, Oo HW et al. Molecular assessment of
artemisinin resistance markers, polymorphisms in the k13
propeller, and a multidrug-resistance gene in the east-
ern and western border areas of Myanmar. Clin Infect Dis
2015;60:1208–15.
O’Flaherty K, Ataı́de R, Zaloumis SG et al. Contribution of func-
tional antimalarial immunity to measures of parasite clear-
ance in therapeutic efficacy studies of artemisinin deriva-
tives. J Infect Dis 2019;220:1178–87.
Olshina MA, Angrisano F, Marapana DS et al. Plasmodium falci-
parum coronin organizes arrays of parallel actin filaments
potentially guiding directional motility in invasive malaria
parasites. Malar J 2015;14:280.
Park SY, Guo X. Adaptor protein complexes and intracellular
transport. Biosci Rep 2014;34:e00123.
Peatey CL, Chavchich M, Chen N et al. Mitochondrial membrane
potential in a small subset of artemisinin-induced dormant
Plasmodium falciparum parasites in vitro. J Infect Dis 2015;212:3
Pieperhoff MS, Schmitt M, Ferguson DJ et al. The role of
clathrin in post-Golgi trafficking in Toxoplasma gondii. PLoS
One 2013;8:e77620.
Rocamora F, Zhu L, Liong KY et al. Oxidative stress and pro-
tein damage responses mediate artemisinin resistance in
malaria parasites. PLoS Pathog 2018;14:e1006930.
Ross LS, Dhingra SK, Mok S et al. Emerging Southeast Asian
PfCRT mutations confer Plasmodium falciparum resistance
to the first-line antimalarial piperaquine. Nat Commun
2018;9:3314.
Rovira-Vallbona E, Van Hong N, Kattenberg JH et al. Efficacy of
dihydroartemisinin/piperaquine and artesunate monother-
apy for the treatment of uncomplicated Plasmodium falci-
parum malaria in Central Vietnam. J Antimicrob Chemother
2020;75:2272–81.
Salamun J, Kallio JP, Daher W et al. Structure of Toxoplasma gondii
coronin, an actin-binding protein that relocalizes to the pos-
terior pole of invasive parasites and contributes to invasion
and egress. FASEB J 2014;28:4729–47.
Saunders DL, Vanachayangkul P, Lon C. Dihydroartemisinin–
piperaquine failure in Cambodia. N Engl J Med 2014;371:484–5.
Schallig H, Tinto H, Sawa P et al. Randomised controlled trial of
two sequential artemisinin-based combination therapy reg-
imens to treat uncomplicated falciparum malaria in African
children: a protocol to investigate safety, efficacy, and adher-
ence. BMJ Global Health 2017;2:e000371.
Siddiqui AA, Saha D, Iqbal MS et al. Rab7 of Plasmodium falciparum
is involved in its retromer complex assembly near the diges-
tive vacuole. Biochim Biophys Acta Gen Subj 2020;1864:129656.
Siddiqui G, Srivastava A, Russell AS et al. Multi-omics based
identification of specific biochemical changes associated
with pfkelch13-mutant artemisinin-resistant Plasmodium fal-
ciparum. J Infect Dis 2017;215:1435–44.
Silva AM, Lee AY, Gulnik SV et al. Structure and inhibition of plas-
mepsin II, a hemoglobin-degrading enzyme from Plasmodium
falciparum. Proc Natl Acad Sci USA 1996;93:10034–9.
Simwela NV, Hughes KR, Roberts AB et al. Experimentally engi-
neered mutations in a ubiquitin hydrolase, UBP-1, modu-
late in vivo susceptibility to artemisinin and chloroquine
in Plasmodium berghei. Antimicrob Agents Chemother 2020;64:
e02484–1900.
Smythe WA, Joiner KA, Hoppe HC. Actin is required for endocytic
trafficking in the malaria parasite Plasmodium falciparum. Cell
Microbiol 2008;10:452–64.
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